CAAP Company: ScarX announces approval for trial of first clinically-promising scar reduction cream

OBIO News
Written By Guest User

Aug 18, 2016 - Toronto-based ScarX Therapeutics (ScarX) has received approval from Health Canada to begin a Phase I clinical trial of its SCX-001 nefopam cream, a first-of-its-kind topical treatment developed to significantly reduce surgical scarring.

For the full press release click here

Guest User
Previous

MaRS announces program to facilitate the development and procurement of breakthrough health technologies in Ontario
Next

Zymeworks’ ZW25 and ZW33 Granted Orphan Drug Designation for Ovarian Cancer by FDA